Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 29, 2026, Context Therapeutics Inc. (the “Company”) received written notice (the “Notification Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”) because the Company’s common stock failed to maintain a minimum…

Entry into a Material Definitive Agreement. On May 14, 2026 (the “Amendment Date”), Context Therapeutics Inc. (the “Company”) entered into a First Amendment (the “Amendment”) to that certain License Agreement, dated September 23, 2024, by and between the Company and BioAtla, Inc. (“BioAtla”) (the “Original License Agreement”). As previously disclosed, pursuant to the Original License Agreement the Company obtained exclusive rights to certain antibody assets, including a Nectin cell adhesion p…

Other Events. As previously disclosed, on March 11, 2026, the Court of Chancery of the State of Delaware (the “Court”) approved a stipulation and proposed consent judgment (the “Stipulated Judgment”) regarding the stockholder class action complaint (the “Action”) filed on February 4, 2026 by the Vladimir Gusinsky Revocable Trust against Context Therapeutics Inc. (the “Company”) and its directors, pursuant to which (i) Article V, Section 2 of the Company’s Amended and Restated Certificate of I…

Other Events. On March 11, 2026, pursuant to the Stipulated Judgment, the Action was dismissed with prejudice as to plaintiff; however, the Court retains jurisdiction to address any mootness fee application. As previously disclosed, the Company’s 2026 Annual Meeting will be held on June 24, 2026 with a record date of April 27, 2026. The Company intends to include on the agenda for the Annual Meeting a proposal for the election of director nominees of the Company to a one-year term and until s…

Other Events. On February 24, 2026, a stipulation and proposed consent judgment (the “Stipulated Judgment”) was filed with the Court of Chancery of the State of Delaware (the “Court”) regarding the stockholder class action complaint (the “Action”) filed on February 4, 2026 by the Vladimir Gusinsky Revocable Trust against Context Therapeutics Inc. (the “Company”) and its directors. Pursuant to the Stipulated Judgment, the parties thereto are asking the Court to determine that (i) Article V, Se…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 28, 2025, Context Therapeutics Inc. (the “Company”) received written notice (the “Extension Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until February 23, 2026 (the “Extension Deadline”), to regain compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Extens…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 27, 2025, Context Therapeutics Inc. (the “Company”) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”) because the Company’s common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive bu…

Director — Richard Berman: Richard Berman resigned from the Board of Directors.

Entry into a Material Definitive Agreement. On December 2, 2024, Context Therapeutics Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Agent”). Pursuant to the terms of the Sales Agreement, the Company may offer and sell shares of the Company’s common stock, $0.001 par value per share (the “Shares”), having an aggregate offering amount of up to $75.0 million from time to time through the Agent. The Agent will use its commercially reas…

Entry into a Material Definitive Agreement. On September 23, 2024 (the “Closing Date”), Context Therapeutics Inc. (the “Company”) entered into a license agreement (the “License Agreement”) with BioAtla, Inc. ("BioAtla"), pursuant to which Company obtained from BioAtla an exclusive, worldwide license to develop, manufacture and commercialize two licensed antibodies (the "Assets"), including BA3362 (renamed by the Company as CT-202), BioAtla’s Nectin-4 x CD3 T cell engaging (TCE) bispecific ant…

Director — Dr. Karen L. Smith and Dr. Luke Walker: The company expanded its board with two highly experienced biopharmaceutical executives.

Entry into a Material Definitive Agreement. On July 9, 2024 (the “Closing Date”), Context Therapeutics Inc. (the “Company”) entered into an asset purchase agreement (the “Purchase Agreement”) pursuant to which the Company acquired (the "Transaction") CT-95 (formerly known as LNK-101), a mesothelin x CD3 T cell engaging bispecific antibody, from Link (assignment for the benefit of creditors), LLC (the “Seller”), which succeeded to the assets of Link Immunotherapeutics Inc. The U.S. Food and Dr…

Unregistered Sales of Equity Securities. The disclosures set forth in

Entry into a Material Definitive Agreement On May 1, 2024, Context Therapeutics Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of (i) 59,032,259 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $1.55 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) t…

Other Events. On April 26, 2024, the FDA cleared the Company's IND application to evaluate CTIM-76. With this IND cleared, the Company announced that it plans to initiate a Phase 1 clinical trial to establish the safety, preliminary efficacy, and feasibility of CTIM-76. On May 2, 2024, the Company issued press releases noting that the Company expects that the net proceeds from the Private Placement, together with the Company’s existing cash and cash equivalents, will extend its cash runway th…

Regulation FD Disclosure. On May 2, 2024, the Company issued a press release announcing the Private Placement. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. On May 2, 2024, the Company also issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has cleared the Company's investigational new drug ("IND") application to evaluate CTIM-76, a Claudin 6 (“CLDN6”) x CD3 bispecific a…

Entry into a Material Agreement . On February 29, 2024, Context Therapeutics Inc. (the “Company”) amended its collaboration and licensing agreement with Integral Molecular, Inc. (“Integral”) (the “Integral License Agreement”) for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy (the "Licensed Rights"). In the course of the Company's further due diligence review of its CTIM-76 asset developed under the Integral License Agreement ("CTIM-76"), the Company determined t…